The Lipid Droplet as a Potential Therapeutic Target in NAFLD

被引:43
作者
Goh, Vera J. [1 ]
Silver, David L. [1 ]
机构
[1] Duke NUS Grad Med Sch, Signature Res Program Cardiovasc & Metab Disorder, Singapore 169857, Singapore
基金
英国医学研究理事会;
关键词
nonalcoholic fatty liver disease; lipid droplets; triglyceride; FATTY LIVER-DISEASE; SEIP CONGENITAL LIPODYSTROPHY; TRIGLYCERIDE TRANSFER PROTEIN; PPAR-GAMMA; ENDOPLASMIC-RETICULUM; INSULIN-RESISTANCE; HEPATIC STEATOSIS; APOLIPOPROTEIN-B; PHOSPHATIDYLCHOLINE SYNTHESIS; TRIACYLGLYCEROL SYNTHESIS;
D O I
10.1055/s-0033-1358521
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is a growing problem worldwide. Nonalcoholic fatty liver disease is characterized by an abnormal accumulation of triglyceride-rich lipid droplets (LDs) in the liver, which can lead to liver inflammation and metabolic disturbances. Lipid droplets are dynamic organelles that have recently gained considerable scientific interest. Their formation and growth are regulated processes requiring the participation of many endoplasmic reticulum- (ER-) and LD-associated proteins, which may serve as potential therapeutic targets for NAFLD. Protein families such as fat-inducing transmembrane proteins 1 and 2 (FITM1/FIT1 and FITM2/FIT2), the CIDE family of proteins, and the perilipin family, play important roles in LD biology. In this review, the authors discuss current views on LD formation and growth, and how various proteins may affect LD metabolism and lipoprotein assembly in the pathogenesis of NAFLD.
引用
收藏
页码:312 / 320
页数:9
相关论文
共 50 条
  • [31] The great potential of flavonoids as candidate drugs for NAFLD
    Li, Liangge
    Qin, Yiming
    Xin, Xijian
    Wang, Shendong
    Liu, Zhaojun
    Feng, Xiujing
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 164
  • [32] The biology of lipid droplet-bound mitochondria
    Veliova, Michaela
    Petcherski, Anton
    Liesa, Marc
    Shirihai, Orian S.
    SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2020, 108 : 55 - 64
  • [33] Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD
    Nobili, Valerio
    Alisi, Anna
    Musso, Giovanni
    Scorletti, Eleonora
    Calder, Philip C.
    Byrne, Christopher D.
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2016, 53 (02) : 106 - 120
  • [34] Lipid droplet biogenesis and functions in health and disease
    Zadoorian, Armella
    Du, Ximing
    Yang, Hongyuan
    NATURE REVIEWS ENDOCRINOLOGY, 2023, 19 (08) : 443 - 459
  • [35] Lipid droplet biogenesis
    Wilfling, Florian
    Haas, Joel T.
    Walther, Tobias C.
    Farese, Robert V., Jr.
    CURRENT OPINION IN CELL BIOLOGY, 2014, 29 : 39 - 45
  • [36] Synergy between NAFLD and AFLD and potential biomarkers
    Lakshman, Raj
    Shah, Ruchi
    Reyes-Gordillo, Karina
    Varatharajalu, Ravi
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2015, 39 : S29 - S34
  • [37] Establishing the lipid droplet proteome: Mechanisms of lipid droplet protein targeting and degradation
    Bersuker, Kirill
    Olzmann, James A.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2017, 1862 (10): : 1166 - 1177
  • [38] Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes
    Kim, Moon-Sun
    Lee, Kyoung-Tae
    Iseli, Tristan J.
    Hoy, Andrew J.
    George, Jacob
    Grewal, Thomas
    Roufogalis, Basil D.
    LIVER INTERNATIONAL, 2013, 33 (10) : 1583 - 1593
  • [39] Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: A promising drug Potentilla discolor Bunge
    Ji, Longshan
    Li, Qian
    He, Yong
    Zhang, Xin
    Zhou, Zhenhua
    Gao, Yating
    Fang, Miao
    Yu, Zhuo
    Rodrigues, Robim M.
    Gao, Yueqiu
    Li, Man
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (09) : 3529 - 3547
  • [40] Therapeutic potential and research progress of diosgenin for lipid metabolism diseases
    Zhang, Shi-Zhao
    Liang, Peng-Peng
    Feng, Ya-Nan
    Yin, Guo-Liang
    Sun, Feng-Cui
    Ma, Chao-Qun
    Zhang, Feng-Xia
    DRUG DEVELOPMENT RESEARCH, 2022, 83 (08) : 1725 - 1738